Considering that the RT-associated cancer risk increases due to lack of restoration from tissue damage following DNA-damaging RT in TP53 carriers, mastectomy is the recommended surgical management for such patients, whereas RT is necessary for breast-conserving surgery (BCS) [12–14]. This evidence concerns the gene TP53 and cancer.